UCB is a global biopharma focused on severe diseases in two therapeutic areas: central nervous system and immunology operations.
The company is listed on the Euronext Brussels Stock Exchange and has its headquarters in Brussels, Belgium. It employs more than 8,500 people in more than 40 countries.
Financial Data
-
31st Dec 19 Source: CRO
- €1.1 million turnover
-
-€0.6 million
profit - 0 employees
-
31st Dec 18 Source: CRO
- €36.9 million turnover
-
€25.8 million
profit - 1 employees
- 11 more years available »
Ranking
By Turnover
(€1.1 million)- 964th in Top Companies
- 96th in Health
- 82nd in Pharma
By Employees
(0)- 1026th in Top Companies
- 94th in Health
- 80th in Pharma
-
- 0
- €1.1 million
Employees
- Steve Turley CEO/Managing Director
Latest News
- 10:01pm Dublin ranked seventh best city in world to visit by Lonely Planet
- 8:06pm Nama records after-tax profit of €99m for second quarter of year
- 8:06pm Nama records after-tax profit of €99m for second quarter of 2021
- 7:26pm Sunak’s budget signals clear break with previous austerity policies
- 7:18pm Rent the Runway hits $1.7bn valuation after shares open at $23